Mounjaro (tirzepatide) Injections (weekly)

Mounjaro (tirzepatide) is a once‑weekly prescription injection licensed in the UK for two main purposes: chronic weight management and the treatment of type 2 diabetes. For weight loss, it is prescribed to adults aged 18 and over with: A body mass index (BMI) of 30 kg/m² or more (obesity), or A BMI of 27 kg/m² to 30 kg/m² (overweight) and at least one weight‑related health condition, such as high blood pressure (hypertension), high cholesterol (dyslipidaemia), prediabetes, or heart problems. Mounjaro must be used alongside a reduced‑calorie diet and increased physical activity. It is not a quick fix but a long‑term medical treatment that helps regulate appetite and food intake. Access Doctor provides Mounjaro as a private prescription option for suitable patients following a thorough online consultation.

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist—the first of its kind. It works through two natural hormone pathways: GIP (glucose‑dependent insulinotropic polypeptide) and GLP-1 (glucagon‑like peptide‑1) receptors are both activated, which slows stomach emptying and helps you feel fuller for longer after eating. It acts on areas of the brain that control appetite and cravings, reducing hunger and helping you feel satisfied with smaller portions. It also improves how the body handles blood sugar, which can be particularly beneficial for people with type 2 diabetes or prediabetes. In clinical trial, adults taking the highest dose of Mounjaro (15 mg) alongside diet and exercise achieved an average weight loss of 22.5% of their starting body weight over 72 weeks. This dual‑action mechanism is why many people searching "Mounjaro weight loss UK" are looking for a treatment that can deliver clinically meaningful, sustained results.

The Mounjaro dosing follows a gradual step‑up approach to help your body adjust and minimise gastrointestinal side effects. The standard schedule is: Weeks 1–4: 2.5 mg once weekly (starting dose) Weeks 5–8: 5 mg once weekly Thereafter, the dose may be increased in at least 4‑week intervals through 7.5 mg, 10 mg, 12.5 mg, up to a maximum of 15 mg once weekly, depending on tolerability and clinical response. There is no single "maintenance dose" that suits everyone—your Access Doctor prescriber will work with you to find the most effective and tolerable dose for your individual needs. The Mounjaro KwikPen contains four fixed doses, covering a month's treatment per pen. If you miss a dose and there are more than 4 days (96 hours) until your next scheduled injection, take it as soon as you remember; if less than 4 days remain, skip the missed dose and continue as normal.

The most frequently reported Mounjaro side effects are gastrointestinal and are most noticeable when starting treatment or increasing the dose. They are usually mild to moderate and tend to improve over time: Nausea (the most commonly reported symptom) Diarrhoea Vomiting Constipation Abdominal (tummy) pain or discomfort Indigestion (dyspepsia), dizziness, and tiredness Starting with a low dose and increasing gradually helps the body adapt. At Access Doctor, your clinician will advise you on how to manage these common reactions and when to seek further help. Staying well hydrated and eating smaller, lower‑fat meals can also reduce gastrointestinal upset.

Mounjaro is not suitable for everyone. The UK MHRA has strengthened warnings about the risk of acute pancreatitis (inflammation of the pancreas), including rare reports of necrotising and fatal pancreatitis, with all GLP-1 and dual GLP-1/GIP receptor agonists. You must seek urgent medical attention if you experience severe, persistent abdominal pain that may radiate to your back, accompanied by nausea and vomiting, as this could be a sign of pancreatitis. If pancreatitis is confirmed, Mounjaro must be stopped and not restarted. Other important risks include: Gallbladder problems, including gallstones and cholecystitis. Severe hypoglycaemia in people with diabetes, particularly if combined with insulin or sulphonylureas. Kidney injury from dehydration caused by vomiting or diarrhoea. Important contraceptive warning: Mounjaro may reduce the effectiveness of the oral contraceptive pill. Women using oral contraceptives should use a barrier method of contraception (such as condoms) for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. Your Access Doctor online consultation includes a full medical history review to ensure Mounjaro is safe and appropriate for you.

Mounjaro is a prescription‑only medicine (POM), so you cannot buy it over the counter. You need a valid prescription from a UK‑registered healthcare professional. Many people search "buy Mounjaro online UK" or "Mounjaro cost UK" to understand their options. The list price for a month's supply of Mounjaro on a private prescription typically ranges from around £120 to £340 per month, depending on the dose strength and the pharmacy you choose. Higher‑dose pens (12.5 mg and 15 mg) are more expensive than the lower starting doses. At Access Doctor, we offer competitive Mounjaro pricing, and your final cost is clearly shown once you select your treatment during the online consultation. On the NHS, Mounjaro is being introduced through a phased rollout for people who meet strict eligibility criteria, and access remains limited for many. This is why many people choose the private route for faster, more direct access with discreet home delivery.

This is one of the most common questions asked by people searching "Mounjaro vs Wegovy UK". Here are the key differences: Mounjaro (tirzepatide) vs Wegovy (semaglutide): How it works: Mounjaro uses a dual GIP/GLP-1 receptor agonist (two hormone pathways); Wegovy uses a GLP-1 receptor agonist (one hormone pathway). Licensed for: Mounjaro is licensed for type 2 diabetes AND chronic weight management; Wegovy is licensed for chronic weight management (and cardiovascular risk reduction). Maximum dose: Mounjaro 15 mg once weekly; Wegovy 2.4 mg once weekly. Average weight loss in clinical trials: Mounjaro ~22.5% of starting body weight at 72 weeks (15 mg dose); Wegovy ~15% of starting body weight at 68 weeks. Pen type: Mounjaro uses a KwikPen (multi‑dose, 4 doses per pen); Wegovy uses a single‑dose pre‑filled pen (one pen per injection). Clinical trial data suggest Mounjaro produces greater average weight loss than Wegovy, due to its dual‑hormone mechanism. However, individual response varies, and the right choice depends on your health profile, medical history, and how you tolerate each medication. Your Access Doctor prescriber can help you understand which option may be more suitable for you.

The Mounjaro KwikPen is a multi‑dose, pre‑filled pen that contains four fixed doses—one for each week of a month's treatment. Here is a simplified guide: 1. Prepare: Wash your hands. Remove the pen cap and wipe the red inner seal with an alcohol swab. 2. Attach a new needle: Always use a fresh pen needle for each injection. Remove the paper tab, push the needle straight onto the pen, and screw it until tight. Remove both needle caps. 3. Prime the pen: Turn the dose knob until it clicks and you see a small amount of medicine released from the needle tip. This ensures the pen is working correctly. 4. Dial your dose: Turn the dose knob until it stops and the number "1" is visible in the dose window. 5. Inject: Choose a site—lower stomach (abdomen), thigh, or upper arm. Rotate the site each week. Push the needle into the skin, press and hold the dose button, and slowly count to 5 before removing the needle. 6. Dispose: Remove the needle safely and place the used pen in a sharps bin. Never share your pen with others. You can inject at any time of day, with or without food. The Mounjaro KwikPen from Access Doctor comes with full instructions, and we are here to support you if you have any questions.

In clinical trials, measurable Mounjaro results were typically seen within the first few months, with progressive weight loss continuing through 72 weeks of treatment. Many patients searching "Mounjaro before and after UK" highlight a gradual but clinically significant transformation when treatment is maintained alongside diet and lifestyle changes. NICE guidance recommends that if you have not lost at least 5% of your initial body weight after 6 months on the highest tolerated dose, your healthcare professional should reassess whether continuing treatment is appropriate for you. At Access Doctor, your prescriber will review your progress regularly and help you decide on the best ongoing approach.

Yes. Mounjaro is licensed in the UK for both type 2 diabetes and chronic weight management. For people living with overweight or obesity who also have type 2 diabetes, Mounjaro can help achieve meaningful weight loss while also improving blood sugar (HbA1c) control. If you take insulin or sulphonylureas, your doctor may need to adjust your diabetes medication to reduce the risk of hypoglycaemia (low blood sugar). Your Access Doctor consultation includes a full health review to guide safe, personalised use.

The NHS is rolling out Mounjaro through a phased implementation plan. During the initial phase (from June 2025), NHS eligibility is limited to people with: A BMI of 40 kg/m² or higher (or 37.5 kg/m² or higher for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African‑Caribbean backgrounds), and At least four of the following weight‑related health conditions: hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. The full rollout is expected to take several years, and many people who meet the broader NICE criteria (BMI ≥35 with at least one comorbidity) may not yet be able to access Mounjaro on the NHS. If you don't qualify, or prefer a quicker, more accessible route, Access Doctor offers private online prescriptions after a review by a UK‑registered clinician, with discreet home delivery.

Mounjaro is designed for long‑term weight management, not a short‑term fix. If you stop injecting Mounjaro without implementing lasting lifestyle changes, appetite and hunger may return to previous levels, and weight regain is common. Clinical evidence shows that the medication's effects on appetite and satiety are maintained only while treatment continues. NICE recommends that people stopping weight‑loss medications should receive structured follow‑up support for at least a year to help maintain weight loss. If you are thinking about stopping, your Access Doctor prescriber can help you create a transition plan to protect your progress.